Background: Oral emtricitabine/tenofovir (FTC/TDF)-based pre-exposure prophylaxis (PrEP) has been shown to prevent acquisition of HIV. PrEP is a promising, yet resource-intensive prevention strategy with high drug and monitoring costs. Providers and policy makers need evidence-based guidance to make decision on prioritizing populations for PrEP. This talk will discuss development of optimal strategies for identifying subgroups for which PrEP will have maximum impact. Conclusions: The efficient prioritization for subgroups tracks with the effectiveness of PrEP as measured by the absolute (rather than relative) difference in HIV incidence rates. Populations for which this difference is maximized have a lowest number of individuals needed to treat (NNT) per infection prevented. Underlying HIV incidence and relative efficacy (and hence adherence) determine the absolute change in HIV rates due to PrEP. Hence, lower adherence in some settings may be offset by higher underlying HIV incidence and need not preclude the efficient delivery of PrEP. The population impact of PrEP prioritization strategies will be largely determined by the concentration of HIV incidence within that subpopulation _ summarized by the population attributable fraction. Additional considerations for deployment include cost, resistance, toxicity and indirect effects on HIV by interrupting HIV transmission networks. We will illustrate these considerations by combining results of published modeling studies with results from the iPrEx trial (Grant et al, 2010) – a randomized study of daily FTC/TDF based PrEP in men who have sex with men.